Auro Laboratories Quarterly Results for Trading Insights
In Sept 2025, Auro Laboratories (AUROLAB) reported revenue ₹10 Cr and net profit ₹1 Cr — revenue +233.3% YoY. For annual financials, live price and key ratios, visit AUROLAB screener.
AUROLAB Quarterly Results — Revenue, Profit & EPS Highlights
Auro Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Auro Laboratories stock price data download to track price trends across different timeframes.
- Revenue of ₹10 Cr in Sept 2025 (+233.3% vs Jun 2025, +233.3% vs Sept 2024)
- Net Profit of ₹1 Cr in Sept 2025
- EBITDA of ₹3 Cr in Sept 2025
- Operating Margin of 27.0% in Sept 2025 (+26.0pp vs Jun 2025)
- Earnings Per Share of ₹1.15 in Sept 2025 (+776.5% vs Jun 2025)
Auro Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
AUROLAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Jun 2025 | Sept 2024 | Jun 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 10 | 3 | 3 | 6 | 233.3% | 233.3% |
| Net Profit (₹ Cr) | 1 | 0 | 0 | 1 | - | - |
| EBITDA (₹ Cr) | 3 | 0 | 1 | 2 | - | - |
| EPS (₹) | 1.15 | -0.17 | 0.57 | 1.21 | - | - |
| Operating Margin (%) | 27.0% | 1.0% | 23.0% | 23.0% | - | - |
AUROLAB Share Price Trend — 1-Year Movement Across Quarterly Results
Auro Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with AUROLAB fundamental valuation to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
AUROLAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Auro Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1862.9 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 164.9 |
|
Divis Laboratories
Mar 2026 |
₹175,434.91 Cr | 6787.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 239.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹149,924.56 Cr | 4457.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 387.2 |
|
Zydus Life Science
Mar 2026 |
₹109,226.70 Cr | 1085.5 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 85.8 |
|
Cipla
Mar 2026 |
₹109,195.79 Cr | 1415.7 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.1 |
All amounts in ₹ Crores